Carlsmed Inc (CARL) — Titan Protect Analysis

CARL

Carlsmed Inc

Healthcare · ·

$11.07

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$281M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.19

Based on estimated future earnings — lower means cheaper

Rev Growth

+58.2%

Year-over-year revenue change

Profit Margin

-57.8%

How much profit the company keeps from each dollar of revenue

ROE

-52.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$18.00

+63% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Carlsmed Inc

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorpora

https://carlsmed.com

Country: United States Employees: 127 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.058

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0247

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.545

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-26.2%

Historical annualised return based on price data

Max Drawdown

-48.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

105

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$17.19

36% below the year high

52W Low

$8.50

30% above the year low

Avg Volume

156,366

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.98

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

18.71

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

75.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-57.6%

Profit from core operations before interest and tax

Free Cash Flow

$-26,400,876

Negative — the business is spending more than it generates

Revenue (TTM)

$56M

Total revenue over the last 12 months

Net Income

$-32,601,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$23.00

Target Median

$18.00

Target Low

$16.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
6 May2026	Dave McCormick	Republican	buy	500K–1M
2026-05-06	Dave McCormick	Republican	Purchase	500K–1M

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go